Results 171 to 180 of about 843,559 (297)

Humanized Antibodies Targeting Ectodomains of IL-6R and GP130 Suppress IL-6/STAT3 Signalling and Tumour Growth in Breast Cancer Models. [PDF]

open access: yesJ Cell Mol Med
Pereira SD   +10 more
europepmc   +1 more source

Peanut‐Specific IgG4 mAbs Promote Regulatory Immune Responses Ex Vivo and Improve Oral Immunotherapy in Mice

open access: yesClinical &Experimental Allergy, EarlyView.
Allergen‐specific IgG4 mAbs were shown to block facilitated IgE binding to B cells and redirect allergens towards myeloid APC, leading to increased IL‐10 production in vitro. In combination with oral AIT, the mAbs inhibited mast cell activation and sustained allergen‐specific IgG4 levels in an in vivo model of peanut allergy. ABSTRACT Background Peanut
Pascal Gasser   +12 more
wiley   +1 more source

Bullous Eruption Associated With Loncastuximab Tesirine in a Patient With Diffuse Large B‐Cell Lymphoma

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Loncastuximab tesirine (LT) is an antibody‐drug conjugate (ADC), a novel class of therapeutics that combines a target‐specific monoclonal antibody with a cytotoxic agent via a chemical linker. LT has been approved in the United States as therapy for relapsed or refractory diffuse large B‐cell lymphoma (DLBCL).
Daniella Jaguan   +2 more
wiley   +1 more source

Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review. [PDF]

open access: yesFront Immunol
Allinovi M   +8 more
europepmc   +1 more source

Early tocilizumab and outcomes in acute necrotizing encephalopathy

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Early tocilizumab and outcome in acute necrotising encephalopathy. Aim To evaluate the timing and safety of tocilizumab in acute necrotizing encephalopathy (ANE). Method This was a multicentre retrospective study evaluating outcomes (modified Rankin Scale [mRS]) in children with ANE treated with tocilizumab. A logistic regression model determined a cut‐
Velda X Han   +14 more
wiley   +1 more source

Treatment Patterns, Outcomes and Survival Trends in T‐Cell Prolymphocytic Leukemia: A Nationwide Population‐Based Study in the Netherlands

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Background T‐cell prolymphocytic leukemia (T‐PLL) is a rare, aggressive mature T‐cell malignancy with limited therapeutic options. Alemtuzumab remains the backbone of therapy, and fit responders are consolidated with allogeneic stem cell transplantation (alloSCT). However, contemporary population‐level outcomes remain poorly defined.
Mirian Brink   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy